Mutations in p53 change the sensitivity to cancer chemotherapeutic drugs. Whereas many drugs, including the vinca alkaloids, often become less eective when p53 is transcriptionally inactivated, several, most notably paclitaxel, may become more eective. In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids. Using murine ®broblasts transfected with MAP4, we directly demonstrated that the changes in drug sensitivity were associated with parallel alterations in drug-induced apoptosis and cell-cycle arrest. Immuno¯uorescent staining of the microtubule network revealed that cells with increased MAP4 expression displayed an increase in polymerized microtubules and an increased binding of uorsceinated paclitaxel. Since MAP4 stabilizes polymerized microtubules, overexpression of this gene provides a plausible mechanism to explain the altered sensitivity to microtubule-active drugs in the presence of mutant p53.
Introduction
The sensitivity to cancer chemotherapeutic drugs is in¯uenced by numerous factors including drug metabolism, uptake, eux, interaction with target sites, and the ability of cells to survive potential lethal damage. Recently, p53, a cellular transcription factor that is frequently mutated in human malignancies, has been implicated in the response to genomic and nongenomic cellular damage (Volgelstein and Kinzler, 1992 ). This appears to be due to a central role for this gene in determining whether cells will growth arrest or enter cell death pathways (apoptosis) (White, 1996) . Cells with wild-type p53 have a propensity towards cell-cycle arrest following DNA damage (Kastan et al., 1991; Lin et al., 1992; Perry and Levire 1993) , whereas cells with mutant p53 appear to bypass the G1/S check point (Gewitz, 1993) . The former response is believed to allow time for repair of cellular damage (Kastan et al., 1992; Hall et al., 1993; Lee et al., 1995) , whereas the latter permits DNA replication at a time when the viability of cells is questioned (Hartwell, 1992) . Under certain circumstances believed to be associated with either overwhelming cellular damage or con¯icting cellular signals (Lane, 1993) , wild-type p53 appears to direct cells down an apoptotic pathway (Clarke et al., 1993; Merritt et al., 1994; Ziegler et al., 1994) . Cells with mutant p53 appear less likely to undergo apoptosis at equivalent levels of cellular damage (Lowe and Bernstein, 1993; Lee et al., 1993; Fan et al., 1994) .
The propensity of cells to undergo apoptosis correlates with the sensitivity to many anti-cancer therapies, including radiation and chemotherapy (Lutzker and Levine, 1996) . Whereas many drugs appear to be less eective in the presence of mutant p53 (Lowe et al., 1993; Fan et al., 1994; Aas et al., 1996) , certain drugs appear to be more active (Fan et al., 1996; Hawkins et al., 1996; Wahl et al., 1996; Waldman et al., 1996) . In contrast, several laboratories have shown a signi®cant increase in sensitivity of cells with mutant p53 to the microtubule stabilizing agent, paclitaxel (Hawkins et al., 1996; Wahl et al., 1996; Wu and El Diery, 1996) . The mechanism(s) by which p53 changes the sensitivity to chemotherapeutic drugs is unknown. A variety of factors could potentially explain the increased sensitivity of cells with mutant p53 to paclitaxel. Since p53 is a transcriptional activation factor, the expression or loss of expression of p53-dependent gene products might aect drug sensitivity. Although the transcription of a variety of genes appears to be activated by wild-type p53, only recently have genes been rigorously shown to be repressed by wild-type p53 (White, 1996) . Murphy et al. (1996) recently reported that MAP4 is transcriptionally repressed in the presence of wild-type p53. In these studies, increased expression of MAP4 was observed when murine embryo ®broblasts harboring a temperature-sensitive p53 mutant were shifted to 398C, allowing expression of the mutant form of the protein. In addition, MAP4 expression was repressed when wild-type p53 was induced by U.V. irradiation. MAP4 stabilizes polymerized microtubules by binding to the negatively charged C-terminus of a-and btubulin (Chapin et al., 1995) . Therefore, p53-regulated changes in expression of MAP4 would alter microtubule dynamic stability and could in¯uence the sensitivity to drugs whose mechanism of action aected the polymerization or depolymerization of these critical cellular components.
In the current studies, we sought to de®ne the relationship between p53 mutation and MAP4 expression. We directly evaluated the eect of MAP4 overexpression on the sensitivity to paclitaxel, vinblastine, and vincristine using a cell line that overexpresses MAP4.
Results
p53 mutation leads to increased MAP4 expression and altered sensitivity to microtubule-active drugs Baby rat kidney (BRK) p53-An1 cells, which express the mutant form of p53(Val135) when grown at 38.58C (Debbas and White, 1993) , were ninefold more sensitive to paclitaxel and fourfold less sensitive to vinblastine at this temperature ( Figure 1A,B) . To exclude the eect of temperature alone on drug sensitivity, identical assays were done using BRK p53-DD cells, which were transfected with the dimerization domain of p53 and behave as a p53 dominant negative mutant at both the permissive and the restrictive temperatures (Sabbatini et al., 1997) . Temperature shift had no signi®cant eect on drug sensitivity of the p53-DD cells (Figure 1 C,D) . In addition, these cells demonstrated similar drug sensitivity as that of the p53-An1 cells grown at 38.58C ( Figure  1A ,B).
To determine whether this alteration in the sensitivities to paclitaxel and vinca alkaloid was associated with the induction of MAP4, we compared MAP4 gene expression at the restrictive and the permissive temperatures in p53-An1 cells. Figure 2 demonstrates that when p53-An1 cells were induced to express p53 in the mutant conformation (Val 135), MAP4 expression increased 5 ± 7-fold.
MAP4 expression leads to increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids To more directly evaluate the eect of MAP4 expression on the sensitivity to antimitotic drugs, we studied the drug sensitivity of A31 murine embryo ®broblasts transfected with a MAP4 expression vector (CBNMAP) compared to that of A31 cells transfected with empty-vector (CMV). As shown in Figure 3 , A31 CBNMAP cells overexpressed 2 ± 5-fold more MAP4 than A31 CMV cells. A31 cells were exposed to paclitaxel or vinblastine for 72 h and cell viability measured by the MTT method. Figure 4A demonstrates that A31 CBNMAP cells were tenfold more sensitive to paclitaxel (IC 50 =200 nM) than cells transfected with the empty vector (IC 50 42 mM). In contrast, Figure 4B shows that A31 CBNMAP cells were more than tenfold resistant to vincristine (IC 50 =1 mM) than cells transfected with empty vector (IC 50 =90 nM). 
MAP4 expression alters drug-induced apoptosis
We next studied the eect of MAP4 overexpression on the ability of chemotherapeutic agents to induce apoptosis. Figure 5 shows that 200 nM paclitaxel induced apoptosis in A31 CBNMAP cells but had no eect on the A31 CMV line. In the case of vinblastine, just the opposite was observed. The A31 CBNMAP cells were resistant to apoptosis at a concentration of vinblastine (200 nM) that induced apoptosis in the A31 cells transfected with empty vector.
MAP4 expression in¯uences cell-cycle distribution in cells treated with paclitaxel and vinblastine
To determine whether the expression of MAP4 changes the eect of drugs on cell-cycle distribution, A31 cells were exposed to vinblastine (200 nM) or paclitaxel (200 nM) for 48 h and analysed using a¯uorescence-activated cell analyser. Overexpression of MAP4 alone did not signi®cantly alter the cell-cycle distribution of A31 cells ( Figure 6A ,B). Paclitaxel treatment increased the accumulation of cells in G2/M in A31 CMV cells ( Figure 6C ), whereas paclitaxel induced an apoptotic shift of the cell population in A31 CBNMAP cells ( Figure 6D ). In contrast, treatment of A31 CMV cells with vinblastine induced an apoptotic peak ( Figure  6E ), whereas vinblastine induced a G2/M arrest in A31 CBNMAP cells ( Figure 6F ).
MAP4 overexpression produces increased polymerization of microtubules
A31 CBNMAP cells had a greater content of polymerized microtubules ( Figure 7A ) than A31 CMV cells ( Figure 7B ) as measured by the binding of a monoclonal a-tubulin antibody to polymerized microtubules. When A31 CBNMAP cells were exposed to paclitaxel, there was a further increase in polymerized microtubules ( Figure 7D ) as compared to that of A31 CMV cells ( Figure 7C ). When A31 CMV cells were exposed to vinblastine, they formed paracrystalline tubulin bundles, structures characteristic of depolymerized microtubules ( Figure 7E ). In contrast, these structures were infrequently seen in A31CBNMAP cells ( Figure 7F ).
MAP4 overexpression leads to increased cellular binding of paclitaxel
To determine whether the increase in MAP4 expression and the subsequent increase in polymerization of microtubules changed the cellular binding of paclitaxel, live A31 cells were incubated with¯uoresceinated paclitaxel and binding was visualized by immunofluorescence microscopy. Changes in¯uorescence intensity were measured by¯uorescent-activated cell analysis. As shown in Figure 8 , A31 CBNMAP cells displayed greater¯uorescence intensity of bound paclitaxel than A31 CMV cells.
Discussion
The discovery of p53 led to a new understanding of the molecular mechanisms of oncogenesis (Levine, 1977) . Unexpectedly, the actions of p53 also control the sensitivity to a variety of cellular damaging agents, including cancer chemotherapeutic drugs. The altera- found that mutant p53 produced resistance to several DNA damaging drugs (Lowe et al., 1993) , several other laboratories found mutant p53 produced an increase in sensitivity to paclitaxel (Hawkins et al., 1996; Wahl et al., 1996; Wu et al., 1996) . Modulation of sensitivity to paclitaxel by loss of wild-type p53 function may also depend on cell type and/or tissuespeci®c genetic background of the tumor cells. For example, disruption of p53 function through the expression of HPV16 E6 protein rendered human ovarian teratocarcinoma cells more than 100-times resistant to paclitaxel (Wu et al., 1996) . In contrast, heterozygous germ line mutations of p53 did not aect sensitivity to paclitaxel in EBV-immortalized lymphoblastoid cells (Delia et al., 1996) . Therefore, in cells with dierent genetic background there may be dierences and/or defects in pathways downstream of p53, which may account for the variation of p53 regulation of taxane sensitivity between normal and transformed cells.
MAP4 expression is increased in cells with mutant p53 and altered drug sensitivity
The recent observation by Murphy et al. (1996) , demonstrating that the MAP4 gene was transcriptionally repressed by wild-type p53 and`derepressed' in the absence of functional p53, led us to investigate the in¯uence of MAP4 expression on the sensitivity to vinblastine and paclitaxel. BRK p53-An1 cells, which harbor a p53 temperature-sensitive (Val 135) mutant, express 5 ± 7-fold more MAP4 when grown at the restrictive temperature (mutant p53) than cells grown at the permissive temperature (wild-type p53) ( Figure  2 ). BRK p53-An1 cells are ninefold more sensitive to taxane and fourfold more resistant to vinca alkaloid at the restrictive temperature ( Figure 1A,B) . The differences in drug sensitivity could not be accounted for by temperature shift alone, since temperature had no eect on the p53-DD cell line, where p53 is functionally mutant at both 328C and 38.58C (Sabbatini et al., 1997) . As anticipated, p53-DD cells display the same drug-sensitivity phenotype as the p53-An1 cells grown at 38.58C ( Figure 1C,D) . The BRK cells have inherently low sensitivity to paclitaxel compared to other but not all cell lines. This was not due to the expression of drug resistance genes such as Pglycoprotein (Zhang and Hait, unpublished data), but more likely due to species-speci®c dierences in sensitivity to antimitotic drugs (Gupta, 1985 (Gupta, , 1988 . Drug sensitivity can also depend on duration of exposure and the method of assaying cell viability. Under certain circumstances the results obtained by MTT assay, which measures the activity of various dehydrogenase enzymes in mitochondria, may not correlate with clonogenic cell survival. This is particularly true with brief durations of exposure when growth may be arrested but cells may survive when placed in drug-free medium. However, in the current studies, the relatively long durations of exposure and correlation with drug-induced apoptosis ( Figure 5 ), strongly suggest that the observed dierences were due to cytotoxicity.
MAP4 transfectants are more sensitive to paclitaxel and more resistant to the vinca alkaloids
To more directly study the in¯uence of MAP4 expression on drug sensitivity, we used A31 cells transfected with either empty vector or a CMV-based expression vector encoding the MAP4 cDNA. Overexpression of MAP4 in transfected A31 cells increases the sensitivity to paclitaxel ( Figure 4A ) and decreases the sensitivity to vincristine ( Figure 4B ). The eect of MAP4 overexpression on vincristine sensitivity was signi®cant at 50 nM and most striking at concentrations greater than 100 nM ( Figure 4B ).
Paclitaxel induces apoptosis in the MAP4 transfectants at concentrations that have no eect on the control cell line (Figure 5 ). In contrast, concentrations The eects of taxanes and vinca alkaloids on cell viability are re¯ected in altered cell-cycle distribution. As shown in Figure 6 , increased MAP4 expression inhibits vinca alkaloid-induced apoptosis and blocks cells in G2/M. In contrast, MAP4 overexpression promotes paclitaxel-induced apoptosis rather than G2/M arrest.
MAP4 function may explain p53-induced changes in drug sensitivity
Paclitaxel binds to polymerized microtubules and inhibits microtubule depolymerization (Horwitz, 1992) . Overexpression of MAP4 in A31 CBNMAP cells increases polymerization of microtubules ( Figure  7B ). MAP4 promotes polymerization of microtubules by binding to the C-terminus of a-and b-tubulin (Yoshida et al., 1996; Nguyen et al., 1997) . Paclitaxel increases microtubular bundling to a greater extent in cells with MAP4 overexpression ( Figure 7D ). As shown in Figure 8 , cells overexpressing MAP4 bind greater amounts of paclitaxel than empty-vector controls.
Vinca alkaloids bind to tubulin monomers and inhibit microtubule polymerization (Lobert et al., 1996) . In the presence of mutant p53 and overexpression of MAP4, the shift of tubulin dynamics from monomers to polymers ( Figure 7A ,B) may decrease the sites of action of vinca alkaloids. Treatment of A31 CMV cells with vinblastine produces paracrystalline tubulin bundles from depolymerized tubulin ( Figure 7E ). These structures are infrequently observed in A31 CBNMAP cells ( Figure 7F) .
Control of MAP4 expression by p53 may have signi®cant therapeutic implications. For example, increased expression of wild-type p53 in response to DNA damage from irradiation or DNA damaging drugs could decrease the sensitivity to taxanes through repression of MAP4. Tishler et al. have shown that taxol and vinblastine may also increase wild-type p53 levels (Tishler et al., 1995) .
In summary, our studies demonstrate that MAP4 gene expression increases sensitivity to paclitaxel and decreases sensitivity to vinca alkaloids. The alterations in drug sensitivity are consistent with the function of MAP4 to promote the polymerization and stabilization of microtubules, which favor the action of drugs that block microtubule depolymerization (e.g., taxanes) over those that block microtubule polymerization (e.g., vinca alkaloids). Since the functional status of p53 regulates MAP4 expression, these studies provide a plausible explanation for the altered sensitivities to taxanes and vinca alkaloids seen in many human malignancies.
Materials and methods

Cell lines and culture conditions
The BRK cell lines used in this study have previously been described (Debbas et al., 1993) . Brie¯y, plasmid pmsvcgval 135 was introduced into primary BRK epithelial cells with the adenovirus E1A gene to generate the transformed cell line p53-An1 (Debbas et al., 1993) . These cells express the murine tsp53(Val 135), a temperaturesensitive protein that assumes the mutant conformation at the restrictive temperature (38.58C) but is predominantly in the wild-type conformation at the permissive temperature (328C) (Debbas et al., 1993) . p53-DD cells were generated from primary BRK cells by transfection of E1A and the dimerization domain of p53 from the pCMVDD plasmid vector that carries the 2.1 Kb intron I of p53. This cell line behaves as a p53 dominant-negative mutant at both the permissive and the restrictive temperatures (Sabbatini et al., 1997) . BRK cells were maintained at 38.58C in an atmosphere of 95% air: 5% CO 2 and grown in monolayer in Dulbecco's Modi®ed Eagle Medium supplemented with 10% fetal bovine serum, 50 units/ml penicillin, and 50 mg/ ml streptomycin.
A31 cell lines were generated from A31 Balbc/3T3 cells, immortalized murine ®broblasts containing wild-type p53. A31 CBNMAP cells were transfected with an expression construct, pCMV-MAP4, encoding the MAP4 cDNA driven by a CMV promotor. A31 CMV cells were transfected with empty vector pCMV-NEO-BAM 3 alone (Baker et al., 1990) and used as controls. A31 cell lines were selected from a single clonal expansion after transfection. p53 status in A31 cells was checked after transfection and subcloning by immunoprecipitation with Ab 421, Ab 240, and Ab 246 and were found to continue to express wild-type p53. A31 cells were maintained in Dulbecco's Modi®ed Eagle Medium supplemented with 10% fetal calf serum, 50 units/ml penicillin, 50 mg/ml streptomycin, and 0.5 mg/ml G418 (Geneticin 1 , Gibco). All cell lines were routinely checked and were found to be free of contamination by mycoplasma and fungi.
Cell viability
Cell viability was assessed by the microculture tetrazolium/ formazan assay (Mosmann, 1983; Scudiero et al., 1988) . 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Chemical Co, St. Louis, MO) was freshly prepared as a 5 mg/ml stock in PBS. The MTT-formazan product was solubilized in 100% DMSO after a 4 h incubation as previously described (Mosmann, 1983; Scudiero et al., 1988) . Absorbance was measured at 550 nm using a Dynatech microplate reader MR5000 (Dynatech Laboratory Inc, Chantilly, VA). Cell viability was expressed as the percentage of the absorbance of drug-treated cells relative to that of the vehicle-treated controls. IC 50 was de®ned as the concentration of drug that produced a 50% decrease in cell viability relative to the vehicle treated controls.
Stock solutions of all drugs were freshly prepared for each experiment and diluted to appropriate concentrations in vehicle immediately before adding to the cells. Paclitaxel (Taxol 1 ) was prepared as a 1 mM stock in absolute ethanol. Vinblastine and vincristine were dissolved in sterile distilled water. All chemicals were purchased from Sigma Chemical Co (St. Louis, MO) unless otherwise indicated.
For drug treatment of BRK p53-An1 cells at the restrictive temperature (38.58C), exponentially growing cells were plated into 96-well tissue culture plates at a density of 2.4610 4 cells per well. Various concentrations of diluted drugs were added to quadruplicate wells (®nal vehicle concentration 41%) and plates were incubated at 38.58C for 18 h. For experiments carried out at the permissive temperature (328C), cells in log phase of growth were shifted from 38.58C to 328C for 24 h to allow the expression of wild-type tsp53 (Debbas and White, 1993) 
Expression of MAP4
Expression of MAP4 by immunoblotting was performed as previously described (Murphy et al., 1996) with minor modi®cations, using the IF5 rat-anti-mouse MAP4 monoclonal supernatant. A 1 : 10 000 dilution in PBSBT (phosphate-buered saline, 1% BSA, and 0.05% Tween-20) of rabbit-anti-rat IgG (Sigma) was used as the secondary antibody in a direct chemiluminescence system (Amersham). Expression of MAP4 in BRK p53-An1 cells in the presence of mutant or wild-type p53 was performed by immunoblotting in cells growing at 38.58C and 328C, respectively. For experiments carried out at the permissive temperature (328C), cells in log phase of growth were shifted from 38.58C to 328C for 24 h to allow the expression of wildtype protein (Sabbatini et al., 1995) .
Cell-cycle analysis
Vehicle or drug-treated A31 cells (approximately 10 6 ) were stained with propidium iodide (10 mg/ml). Fluorescence intensity was determined by¯ow cytometry and pro®les were generated on a Becton Dickson FACScan with laser excitation wavelength set at 488 nm.
Measurement of apoptosis
Vehicle or drug-treated A31 cells were washed free of drugs and DNA extracted as previously described with minor modi®cations (Kondo et al., 1994) . Brie¯y, equal numbers of cells from each treatment were lysed in 350 ml of lysis buer (10 mM Tris, pH 7.4, 150 mM NaCl, 2.5 mM EDTA, 1% Triton X-100) and incubated in the presence of 1 mg/ml Pronase at 378C for 15 min. Cell lysates were then centrifuged at 1200 g for 20 min at 48C. DNA was extracted once with phenol : chloroform, once with chloroform, followed by precipitation with two volumes of ethanol at 7208C overnight. RNA was digested by adding 3 ml of 56 RNAse (10 mg/ml) to 12 ml of DNA sample dissolved in TE buer (10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) followed by incubation for 30 min at 378C. The samples were then electrophoresed in a 1.6% agarose gel in TBE buer (89 mM Tris-borate, pH 8.0 and 2 mM EDTA). DNA was visualized by ethidium bromide staining.
Immuno¯uorescent microscopy of microtubules A31 cells were stained with monoclonal anti-a-tubulin mouse ascites¯uid DM 1A (Sigma) to visualize the microtubule network in control or drug-treated cells. Brie¯y, cells grown on glass coverslips were ®xed in methanol at 7208C after drug treatment. In this procedure, non-polymerized a-tubulin was removed from the cells during ®xation and the washing steps. The ®xed cells were then incubated with a 1 : 100 dilution of primary antibody (DM 1A) in PBS in a moist chamber, followed by incubation with a 1 : 50 dilution in PBS of FITC-goat-antimouse IgG (Sigma) as the secondary antibody and visualized under a¯uorescent microscope (BioRad) using a 100x oil-immersion objective.
Measurement of paclitaxel binding
A31 cells transfected with either empty vector or the MAP4 gene were grown either on glass coverslips or culture dishes followed by incubation with¯uoresceine-conjugated paclitaxel (BODIPT-FL Taxol 1 , Molecular Probe) at a concentration of 200 nM. At dierent time intervals, cells were washed free of unbound paclitaxel and visualized under a¯uorescent microscope. Fluorescence intensity of bound-paclitaxel was determined bȳ ow cytometry and pro®les were generated on a Becton Dickson FACScan analyzer with laser excitation wavelength at 488 nm.
